Recent Updates
Recently added Catalysts
CBLL Positive Sentiment Score: 75/100

Ceribell to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Key Takeaway: Ceribell, Inc. announced that CEO Jane Chao will present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025. The company aims to enhance the diagnosis and management of serious neurological conditions with its innovative Ceribell System. This point-of-care EEG platform has received FDA clearance and is already in use in various acute care settings across the U.S. The presentation will be accessible via a live webcast on Ceribell's website.

Market Sentiment Analysis

POSITIVE FACTORS

  • Ceribell's participation in a prestigious healthcare conference highlights its visibility in the industry.
  • The Ceribell System addresses unmet needs in the acute care setting, indicating strong market relevance.
  • The use of AI in the Ceribell System showcases innovation in medical technology.

Full Press Release Details

SUNNYVALE, Calif., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Ceribell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, will present at the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The presentation will take place on Monday, January 13, 2025, at 7:30 a.m. Pacific Standard Time.
Event: 43rd Annual J.P. Morgan Healthcare Conference
Date: Monday, January 13, 2025
A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About Ceribell, Inc.
Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Brian Johnston or Laine Morgan

Frequently Asked Questions

What is Ceribell, Inc. known for?

Ceribell, Inc. specializes in transforming the diagnosis and management of severe neurological conditions.

When will Ceribell present at the J.P. Morgan Conference?

Ceribell will present on January 13, 2025, at 7:30 a.m. Pacific Time.

What is the Ceribell System?

The Ceribell System is a portable EEG platform for rapid diagnosis and monitoring of neurological conditions.

Where can I watch Ceribell's presentation?

The presentation will be available live and archived on Ceribell's Investor Relations page.

Is the Ceribell System FDA cleared?

Yes, the Ceribell System has FDA 510(k) clearance for indicating suspected seizure activity.

Last updated: Dec 23, 2024